Paradigm Biopharmaceuticals Ltd has released a press release.
PAR Expanded Access IND Cleared by US FDA
Filed with ASX ·
6ix hasn’t read this filing yet.
Paradigm Biopharmaceuticals Ltd. on 6ix
Story so far
Earlier from Paradigm Biopharmaceuticals
- Appendix 4E and 2019 Annual Report
- PARs drug reduces cartilage degradation in subjects with OA
- Paradigm files first ind with US FDA
- Appendix 4C - quarterly
- Paradigm EOFY Update
Later from Paradigm Biopharmaceuticals
- Osteoarthritis pain reduced by Paradigms Zilosul (PPS)
- Paradigm provides regulatory filing update
- Paradigm AGM Presentation
- Paradigm End of Calendar Year Update
- Cleansing Notice and Appendix 3B
Follow Paradigm Biopharmaceuticals into a list and get an email when it puts out news.
Follow Paradigm Biopharmaceuticals